XML 48 R38.htm IDEA: XBRL DOCUMENT v3.8.0.1
Assets and Liabilities Measured at Fair Value (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Jul. 05, 2016
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Jun. 30, 2017
Dec. 31, 2016
Financial assets and liabilities subject to fair value measurements              
Transfer of assets from Level 1 to Level 2   $ 0   $ 0      
Transfer of assets from Level 2 to Level 1   0   0      
Assets:              
Fair value of assets   364,561   364,561     $ 144,754
Liabilities:              
Contingent consideration payable   21,100   21,100     269,722
Derivative liability             265
Deferred compensation plan liability   2,134   2,134     1,479
Fair value of liabilities   23,234   23,234     271,466
Contingent consideration payable              
Balance, beginning of the period   265,350 $ 276,300 269,722 $ 274,077    
Payment of contingent consideration in cash       (10,000) (5,000)    
Payment of contingent consideration in stock         (6,115)    
Changes in fair value during the period, included in Statement of Operations   (244,250) (4,110) (238,622) 9,228    
Balance, end of the period   21,100 $ 272,190 21,100 $ 272,190    
Other current liabilities              
Foreign Currency Exchange Rate Exposure              
Derivative liabilities   0   0     300
MiaMed Inc              
Contingent consideration payable              
Asset acquisition, potential aggregate deal value $ 89,500            
Maximum | Clinical and Regulatory Approval milestones | MiaMed Inc              
Contingent consideration payable              
Contingent consideration payable upon achievement of milestones 83,000            
Maximum | Clinical, Regulatory and Commercial milestones | MiaMed Inc              
Contingent consideration payable              
Contingent consideration payable upon achievement of milestones $ 83,000            
ATB200 Pompe program | Clinical and Regulatory Approval milestones | Callidus              
Liabilities:              
Contingent consideration payable   20,700   20,700      
Commercial paper              
Assets:              
Fair value of assets   123,881   123,881     68,390
Asset-backed securities              
Assets:              
Fair value of assets   30,326   30,326      
Corporate debt securities              
Assets:              
Fair value of assets   207,890   207,890     74,535
Money market              
Assets:              
Fair value of assets   2,464   2,464     1,829
Level 2              
Assets:              
Fair value of assets   364,561   364,561     144,754
Liabilities:              
Derivative liability             265
Deferred compensation plan liability   2,134   2,134     1,479
Fair value of liabilities   2,134   2,134     1,744
Level 2 | Commercial paper              
Assets:              
Fair value of assets   123,881   123,881     68,390
Level 2 | Asset-backed securities              
Assets:              
Fair value of assets   30,326   30,326      
Level 2 | Corporate debt securities              
Assets:              
Fair value of assets   207,890   207,890     74,535
Level 2 | Money market              
Assets:              
Fair value of assets   2,464   2,464     1,829
Level 3              
Liabilities:              
Contingent consideration payable   21,100   21,100     269,722
Fair value of liabilities   $ 21,100   $ 21,100     $ 269,722
Level 3 | ATB200 Pompe program | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Callidus              
Liabilities:              
Discount rate (as a percent)       12.50%      
Level 3 | ATB200 Pompe program | Minimum | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Callidus              
Liabilities:              
Probability of achievement of milestones (as a percent)   58.00%   58.00%   32.00%  
Level 3 | ATB200 Pompe program | Maximum | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Callidus              
Liabilities:              
Probability of achievement of milestones (as a percent)   100.00%   100.00%   45.00%